Delayed Inflammatory Reaction to Hyaluronic Acid Dermal Filler Following Zoledronic Acid Administration: A Case Report
Nada J Alghamdi,1,* Serene R Almuhaidib,2,* Abdulmajeed S Alharbi,2,* Abdullah Ali N Aljalfan,1,* Khalid M Al-Husain1 1Department of Dermatology, King Fahd University Hospital, Al Khobar, Saudi Arabia; 2College of Medicine, Imam Abdulrahman bin Faisal University, Damm...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2024-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Nada J Alghamdi,1,* Serene R Almuhaidib,2,* Abdulmajeed S Alharbi,2,* Abdullah Ali N Aljalfan,1,* Khalid M Al-Husain1 1Department of Dermatology, King Fahd University Hospital, Al Khobar, Saudi Arabia; 2College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia*These authors contributed equally to this workCorrespondence: Abdullah Ali N Aljalfan, Department of Dermatology, King Fahd University Hospital, P.O. Box 34246, Al Khobar, Saudi Arabia, Email A.jalfan7@hotmail.comAbstract: Zoledronic acid is a bisphosphonate that can be administered intravenously and used to treat several bone disorders. It decreases bone resorption, thereby improving bone mineral density (BMD) and reducing fractures. The Food and Drug Administration (FDA) has approved zoledronic acid for the prevention and treatment of osteoporosis in postmenopausal females and males and for other conditions. Zoledronic acid is generally well tolerated, with most side effects being musculoskeletal or gastrointestinal. Cutaneous side effects include maculopapular rash and other mild skin reactions. Rare severe skin rashes, such as toxic epidermal necrolysis, have been reported. Here, we report the case of a 64-year-old female with a medical history of breast cancer status post-radical mastectomy and chemotherapy presenting with delayed hypersensitivity reaction to a hyaluronic acid dermal filler two days after receiving zoledronic acid intravenously given to maintain bone density, symptoms completely resolved with oral prednisolone 20 mg once daily and cetirizine 10 mg. Cases of delayed inflammatory reaction to hyaluronic acid soft tissue filler have previously been reported in patients who have received vaccination or those with viral infections. However, to our knowledge, there have been no reports of delayed inflammatory reactions to facial hyaluronic acid injections after zoledronic acid administration.Keywords: delayed inflammation, filler, zoledronic acid, hyaluronic acid |
|---|---|
| Item Description: | 1178-7015 |